Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to assess the impact of Schistosoma mansoni infection and its treatment on genital immunology and HIV susceptibility in Ugandan women.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Toronto
• Collaborator: UVRI-IAVI HIV Vaccine Program, Uganda
• Treatments: Praziquantel

Criteria

Inclusion Criteria:

• Positive (score above "trace") on a urine CCA rapid test

• Willing to be treated with praziquantel

• Willing to give informed consent, and answer short questionnaires on economic status, and sexual risk behavior.

• Willing to comply with the requirements of the protocol

• HIV and classical STI (see below) negative

Exclusion Criteria:

• HIV infected

• Malaria infected

• Pregnant.

• Irregular menstrual cycle, or actively menstruating at the time of genital sampling.

• Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas vaginalis) or having genital ulcers

• Prior hysterectomy

• Deemed by physician to be unlikely to complete study protocol.